Abstract 3437: Six Months Clinical Outcome in Patients Treated with a Single GenousTM EPC Capturing Stent for Bifurcation Lesions
Aim Restenosis rates of bifurcated lesions remain high, mainly due to side branch (SB) restenosis, even when drug eluting stents (DES) are used. New stent technolgies may reduce restenosis in these complex lesions. The Endothelial Progenitor Cell (EPC)-capturing stent is coated with an antibody (CD34+) that binds circulating EPC’s which differentiate into a functional endothelial layer. This accelerated healing may reduce in-stent restenosis by reducing neointimal hyperplasia and smooth muscle cell proliferation and, in addition, may prevent stent thrombosis. Furthermore, it has been shown that statin therapy increases the EPC number in the peripheral blood. In this single center study, we report the 6 months clinical outcome in patients treated with a single EPC-capturing stent for bifurcated lesions.
Methods Between September 2005 and July 2006, 74 patients were treated with an EPC-capturing stent for a bifurcation lesion. Provisional T-stenting was preferred with a single stent in the main branch (MB), and angioplasty of the SB, aiming at an optimal angiographic result of the MB and an optimal functional result (TIMI 3 flow) of the SB. All patients were treated with statins for at least 2 weeks prior to PCI and dual anti-platelet therapy was prescribed for 1 month. Clinical follow-up was obtained after 6 months.
Results Mean age of the population was 63 years and 78% were male. 12% of the patients were diabetic. Of all bifurcated lesions, 60% was located in the LAD, 20% in the RCX, 16% in the RCA, and 4% in the left main. Mean stent length was 21 ± 6 mm and mean stent diameter was 3.4 ± 0.4 mm. TIMI 3 flow was achieved in all treated lesions. During 6 months clinical follow-up, there were no deaths or myocardial infarctions. Target vessel revascularization was 3% (all patients had a repeat PCI), 1 patients had a non-target vessel revascularization, and no patients died.
Conclusion In the percutaneous treatment of BL using a single EPC-capturing stent results in favourable 6 months clinical outcome comparable to the outcome reported following DES implantation.